Bone marrow toxicity in HCV genotype 5a-infected patient after peg-IFN alpha-2a and ribavirin therapy

Journal of Chemotherapy

Volumn 20, Issue 5, 2008, Pages 648-651

  Drapeau, C M J ^a   Remotti, D ^b   Noto, P ^a   Capone, A ^a   Boumis, E ^a   Petrosillo, Nicola ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b SAN CAMILLO FORLANINI HOSPITAL   (Italy)

Author keywords

Antiviral treatment; Cirrhosis; Myelosuppression; Pancytopenia; Pathogenesis

Indexed keywords

PEGINTERFERON ALPHA2A; PIPERACILLIN PLUS TAZOBACTAM; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RIBAVIRIN;

ADULT; ANAMNESIS; ARTICLE; BLOOD ANALYSIS; BONE MARROW TOXICITY; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ECHOGRAPHY; ERYTHROCYTE COUNT; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HEPATOSPLENOMEGALY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LABORATORY TEST; LEUKOCYTE COUNT; LIVER CIRRHOSIS; LYMPHOCYTE COUNT; MALE; NEUTROPHIL COUNT; PHYSICAL EXAMINATION; SIDE EFFECT; THORAX RADIOGRAPHY; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS LOAD;

EID: 57049148651     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2008.20.5.648     Document Type: Article

References (15)

1. Verna EC, Brown RS. Hepatitis C virus and liver transplantation. Clin Liver Dis 2006; 10:919-40.
2. Kuo A, Terrault NA. Management of hepatitis C in liver transplant recipients. Am J Transplant 2006; 6: 449-58.
3. Strader DB, Wright T, Thomas DL, Seeff LB. AASLD practice guidelines. diagnosis, management and treatment of hepatitisC. Hepatology 2004; 39:1147-71.
4. Peck-Radosavlajevic M, Wichlas M, Homoncik-Kraml M, et al. Rapid suppression of hematopoiesis by standard or pegylated interferon-. Gastroenterology 2002; 123:141-151.
5. Schmid M, Kreil A, Jessner W, et al. Suppression of haematopoiesis during therapy of chronic hepatitis C with different interferon mono and combination therapy. Gut 2005; 54; 1014-1020~
6. De Franceschi L, Fattovich G, Turrini F, et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology 2000; 31: 997-1004.
7. Aman MJ, Keller U, Derigs G, Mohamadzadech M, Huber C, and Peschel C. Regulation of cytokine expression by interferon- in human bone marrow stromal cells: inhibition of hematopoietic growth factors and induction of interleukin-1 receptor antagonist. Blood. 1994; 84: 4142-50.
8. Tarumi T, Sawada K, Sato N, et al. Interferon-alpha-induced apoptosis in human erythroid progenitors. Exp Hematol 1995; 23: 1310-8.
9. Wang Q, Miyakawa Y, Fox N, and Kaushansky K. Interferon- directly represses megakaryopoiesis by inhibiting thrombopoietin-induced signalling through induction of SOCS-1. Blood 2000; 96: 2093-2099.
10. Gomez-Rangel JD, Ruiz-Delgado GJ, Ruiz-Arguelles GJ. Pegylated-interferon induced severe bone marrow hypoplasia in a patient with multiple myeloma receiving thalidomide. Am J Hematol 2003; 74: 290-291.
11. Tefferi A, Elliott MA, Yoon S, et al. Clinical and bone marrow effects of interferon alfa therapy in myelofibrosis with myeloid metaplasia. Blood 2001; 97: 1896.
12. Nguyen MH, Keeffe EB. Prevalence and treatment of HCV genotypes 4, 5, and 6. Clin Gastroenterol Hepatol 2005; 3 (Suppl 2):S97-S101.
13. Bonny C, Fontaine H, Poynard T, et al. Effectiveness of interferon plus RBV combination in the treatment of naive patients with hepatitis C virus type 5. A French multicentre retrospective study [Abstract]. Aliment Pharmacol Ther 2006; 24: 593-600.
14. Legrand-Abravanel F, Sandres-Sauné K, Barange K, et al. Hepatitis C virus genotype 5: epidemiological characteristics and sensitivity to combination therapy with interferon- plus ribavirin. JID 2004; 189: 1397-1400.
15. Thiele J, Kvasnicka HM, Schmitt-Graeff A, et al. Effects of interferon and hydroxyurea on bone marrow fibrosis in chronic myelogenous leukaemia: a comparative retrospective multicentre histological and clinical study. Br J Haematol 2000; 108: 64-71.